Literature DB >> 16432151

Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis.

Charles G Glabe1, Rakez Kayed.   

Abstract

Recent findings indicate that soluble amyloid oligomers may represent the primary pathologic species in degenerative diseases. These amyloid oligomers share common structural features and the ability to permeabilize membranes, suggesting that they also share a common primary mechanism of pathogenesis. Membrane permeabilization by amyloid oligomers may initiate a common group of downstream pathologic processes, including intracellular calcium dyshomeostasis, production of reactive oxygen species, altered signaling pathways, and mitochondrial dysfunction that represent key effectors of cellular dysfunction and cell death in amyloid-associated degenerative disease, such as sporadic inclusion-body myositis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432151     DOI: 10.1212/01.wnl.0000192103.24796.42

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  126 in total

1.  Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.

Authors:  Tobias Högen; Johannes Levin; Felix Schmidt; Mario Caruana; Neville Vassallo; Hans Kretzschmar; Kai Bötzel; Frits Kamp; Armin Giese
Journal:  Biophys J       Date:  2012-04-03       Impact factor: 4.033

2.  Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.

Authors:  Victor L Villemagne; Keyla A Perez; Kerryn E Pike; W Mei Kok; Christopher C Rowe; Anthony R White; Pierrick Bourgeat; Olivier Salvado; Justin Bedo; Craig A Hutton; Noel G Faux; Colin L Masters; Kevin J Barnham
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 3.  Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease.

Authors:  Yanwei Li; Jinying Zhao; Christian Hölscher
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

Review 4.  Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.

Authors:  Houshang Amiri; Kolsoum Saeidi; Parvin Borhani; Arash Manafirad; Mahdi Ghavami; Valerio Zerbi
Journal:  ACS Chem Neurosci       Date:  2013-09-26       Impact factor: 4.418

5.  α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.

Authors:  Zane S Martin; Volker Neugebauer; Kelly T Dineley; Rakez Kayed; Wenru Zhang; Lindsay C Reese; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

6.  In vitro polymerization of a functional Escherichia coli amyloid protein.

Authors:  Xuan Wang; Daniel R Smith; Jonathan W Jones; Matthew R Chapman
Journal:  J Biol Chem       Date:  2006-12-12       Impact factor: 5.157

7.  Orthogonal cross-seeding: an approach to explore protein aggregates in living cells.

Authors:  Justyna Hinz; Lila M Gierasch; Zoya Ignatova
Journal:  Biochemistry       Date:  2008-03-11       Impact factor: 3.162

8.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease.

Authors:  P Hemachandra Reddy; M Flint Beal
Journal:  Trends Mol Med       Date:  2008-01-22       Impact factor: 11.951

9.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

10.  Involvement of α7nAChR in the Protective Effects of Genistein Against β-Amyloid-Induced Oxidative Stress in Neurons via a PI3K/Akt/Nrf2 Pathway-Related Mechanism.

Authors:  Jianbin Guo; Guoqing Yang; Yuqing He; Huiming Xu; Hong Fan; Jing An; Lingling Zhang; Rui Zhang; Guihua Cao; Dingjun Hao; Hao Yang
Journal:  Cell Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.